hereditary angioedema (HAE)
Rare disease · 2010–2024
4decisions
2medicines
2carried consumer input
2individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| lanadelumab Preventative treatment of hereditary angioedema (HAE) Types 1 or 2 in patients aged 2 to less than 12 years who have experienced at least one treated acute… | Nov 2024 | Recommended with restriction | 2 individuals |
| icatibant Symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults with C1-esterase inhibitor deficiency. | Jul 2017 | Recommended | no section in document |
| icatibant Symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults with C1-esterase-inhibitor deficiency. | Nov 2016 | Noted | input received |
| icatibant Treatment of laryngeal/oro-pharyngeal and severe abdominal attacks of acute hereditary angioedema (HAE) in patients with confirmed C1-esterase inhibitor… | Jul 2010 | Not recommended | no section in document |
What the PBS pays
$50M in government benefit over 2024–25, across 2,678 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| lanadelumab | $48.1M |
| icatibant | $2.3M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 3 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.